| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Equillium, Inc.$2.91
-0.05 (-1.69%)
D 39Pipeline Score Fair Value Biotech · Commercial
Market Cap
142.89 M
EPS
-0.32
P/E Ratio
-
Value Trade
11.86 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
2.99 M
Operating CF
-4.30 M
Total Assets
63.08 M
Total Liabilities
3.60 M
Equity
59.49 M
D/E Ratio
12,345
-12.4 %
Week
2.73 %
1 Month
23.5 %
3 Month
117.31 %
6 Month
-66.32 %
5 Year
-84.25 %
All Time
Cash Data
Cash Position
61.32 M
Monthly Burn
1.43 M
Runway
41.1 mo
Burn Trend
SEC Filing
May 13, 2026
Overview
Volume
1.76 M
52 Week Range
0.27 - 2.70
% held by Insiders
20.43 %
% held by Institutions
57.02 %
Enterprise Value
82.26 M
Total Shares
63.24 M
Short %
11.42 %
Float Shares
44.78 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Equillium, Inc.
311Total events
4Upcoming
91Tier-1 (high impact)
2018 – 2029Coverage
Upcoming catalysts 4
Event history 307
Jun 3, 2026
May 27, 2026
May 13, 2026
Apr 28, 2026
◆Oral PresentationPresentation
Equillium management presenting at Oppenheimer's 2026 Innovation on the Island Event
Apr 18, 2026
◆Poster PresentationEQ504Presentation
Poster presentation: EQ504, a Potent AhR Modulator, Promotes Epithelial Repair and Barrier Restoration Compared to Clinically Validated AhR Agonists
ulcerative colitissource ↗
Apr 16, 2026
◆Poster PresentationEQ504Presentation
Poster presentation: EQ504: A Novel AhR Modulator That Promotes Immune Tolerance Through Il-10 and Il-22 Cytokine Release
ulcerative colitissource ↗
Q2 2026
◆Trial InitiationEQ504Trial
Phase 1 proof-of-mechanism study initiation expected mid-2026
ulcerative colitissource ↗
Apr 2026
▲Oral PresentationEQ504Presentation
Presented two EQ504 abstracts at IMMUNOLOGY2026
ulcerative colitissource ↗
Mar 23, 2026
◆Oral PresentationPresentation
Equillium management to participate in fireside chat at 38th Annual Roth Conference
Mar 13, 2026
▼Equity OfferingCorporate
Equillium announces $35 million PIPE financing with RA Capital Management
Drug Pipeline Intelligence
D39
Pipeline Score $102M
Pipeline ValueFair Value
Valuation Signal4
Drugs Scored0.7x
rNPV / MCap Top 56%
Micro Cap (rank 402 of 911)
Percentile RankEquillium, Inc. faces pipeline headwinds (39/100), with $817M risk-adjusted pipeline value, led by EQ001 in Asthma (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EQ001 Monoclonal antibody | Acute-graft-versus-host Disease | Phase 1 | NCT03763318 | 18% | $403M | COMPLETED | 30 | - | - | Nov 21, 2022 | - | Apr 18, 2025 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
itolizumab | acute graft-versus-host disease | Phase 3 | 2025-03-27 | duration of CR: median 336, p value 0.017; failure free survival: median 154, p value 0.043; CR at Day 99: patients itolizumab 35, patients placebo 22, p value 0.035; overall survival trend: mortality itolizumab 19, mortality placebo 25 Read More | Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights Announced topline data from the Phase 3 EQUATOR study in first-line acute graft-versus-host disease Break Read More | |
itolizumab | acute graft-versus-host disease | Phase 3 | 2025-03-27 | duration of CR: median 336, p value 0.017; failure free survival: median 154, p value 0.043; CR at Day 99: patients itolizumab 35, patients placebo 22, p value 0.035; overall survival trend: mortality itolizumab 19, mortality placebo 25 Read More | Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights Announced topline data from the Phase 3 EQUATOR study in first-line acute graft-versus-host disease Break Read More | |
itolizumab | acute graft-versus-host disease | Phase 3 | 2025-03-27 | duration of CR: median 336, p value 0.017; failure free survival: median 154, p value 0.043; CR at Day 99: patients itolizumab 35, patients placebo 22, p value 0.035; overall survival trend: mortality itolizumab 19, mortality placebo 25 Read More | Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights Announced topline data from the Phase 3 EQUATOR study in first-line acute graft-versus-host disease Break Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in EQ
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
EQ Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
EQ▲ +11.5%on this news
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 2, 2026
Equillium, Inc. announced the grant of nonstatutory stock options to a new employee under its 2024 Inducement Plan. The award consists of 145,000 shares with an exercise price of $3.08, vesting over four years. This grant is in accordance with Nasdaq Listing Rule 5635(c)(4), reflecting the company's commitment to attracting talent.
Read more →EQ▲ +8%on this news
Equillium to Participate in the 2026 Jefferies Global Healthcare Conference
Equillium, Inc. announced its participation in the 2026 Jefferies Global Healthcare Conference, scheduled for June 3, 2026. The management team will engage in a fireside chat and is available for investor meetings. This highlights Equillium's commitment to connecting with stakeholders and promoting its innovative therapies for autoimmune and inflammatory disorders.
Read more →EQ▲ +16.7%on this news· ran to +31% by day 3
Equillium to Host Virtual Investor Event to Share New Insights into the Aryl Hydrocarbon Receptor (AhR) and miR-124 Axis
Equillium, Inc. is set to host a virtual investor event on May 27, 2026, led by Chief Scientific Officer Stephen Connelly, to present new preclinical data regarding the Aryl Hydrocarbon Receptor (AhR) and its interaction with miR-124. The session will discuss the implications of these findings for therapeutic development in autoimmune and inflammatory disorders. Notably, the webinar aims to clarify the complex relationship between AhR activation and miR-124 induction, which has been controversial in previous studies.
Read more →EQEquillium Reports First Quarter 2026 Financial Results and Corporate Highlights Phase 1 proof-of-mechanism study of EQ504 on track to initiate in mid-2026, with data expected approximately six months thereafter Equillium
Equillium has reported its financial performance for Q1 2026, revealing a net loss of $5.3 million, improved from the prior year's loss. The company is preparing to initiate a Phase 1 proof-of-mechanism study for its drug candidate EQ504, targeting inflammatory diseases, with data expected to be released about six months post-initiation. Financial resources are projected to sustain operations until 2029, enhanced by a recent $35 million financing. Furthermore, Equillium has strengthened its leadership team with the appointment of Dr. Snehal Naik as Chief Development Officer to oversee clinical development and strategy.
Read more →EQEquillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 1, 2026
Equillium, Inc. announced the grant of 800,000 stock options to two new employees as part of its 2024 Inducement Plan. The options have an exercise price of $2.08, which is equal to the company's closing stock price on the grant date. The vesting schedule spans four years, contingent on continued employment.
Read more →EQEquillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Equillium, Inc. announced the grant of inducement stock options totaling 800,000 shares to two new employees, in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price of $2.08 and will vest over four years. The company's lead candidate, EQ504, is designed to treat severe autoimmune and inflammatory disorders such as ulcerative colitis and lung diseases. The announcement underscores Equillium's growth trajectory as well as the potential challenges that lie ahead, aligned with industry-wide risks in clinical development.
Read more →EQ▲ +7%on this news
Equillium to Participate in Oppenheimer’s 2026 Innovation on the Island Event
Equillium, Inc. will present at Oppenheimer's 2026 Innovation on the Island Event on April 28, 2026. The management team will also be available for meetings with registered investors. The company focuses on developing novel therapies for autoimmune and inflammatory disorders, with EQ504 as their lead candidate.
Read more →EQ▼ -6.2%on this news
Equillium Announces Poster Presentations at IMMUNOLOGY2026™, the Annual Meeting of the American Association of Immunologists
Equillium, Inc. announced that new preclinical data for EQ504 will be presented at IMMUNOLOGY2026™, the annual meeting of the American Association of Immunologists. The presentations will focus on EQ504's role as a potent AhR modulator, which may enhance immune responses and promote mucosal healing in conditions like ulcerative colitis. The event will take place in Boston from April 15-19, 2026.
Read more →EQEquillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 2, 2026
Equillium, Inc. announced the grant of stock options to a new employee under its 2024 Inducement Plan. The award consists of 32,000 nonstatutory stock options with an exercise price of $2.04, vesting over four years. This grant aligns with Nasdaq Listing Rule 5635(c)(4) and aims to attract talent to support the company's growth in developing therapies for autoimmune disorders.
Read more →EQEquillium Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate and Clinical Highlights
Equillium, Inc. reported its financial results for Q4 and full year 2025, highlighting a transformative year focused on advancing EQ504. The company plans to initiate a Phase 1 study of EQ504 in mid-2026, with expectations of data six months later. Despite no revenue in 2025, Equillium's cash position is projected to support operations until 2029.
Read more →EQEquillium to Participate in the 38th Annual Roth Conference
Equillium, Inc. will participate in the 38th Annual Roth Conference on March 23, 2026. The management team will be available for investor meetings, showcasing their commitment to investor engagement. The company focuses on developing therapies for severe autoimmune and inflammatory disorders, with their lead candidate EQ504 showing promise in treating conditions like ulcerative colitis.
Read more →EQ▲ +19.3%on this newsshared move
Equillium Announces $35 Million Financing with RA Capital Management
Equillium, Inc. has announced a $35 million financing agreement with RA Capital Management to support the clinical development of its investigational therapy EQ504. The funds will help extend the company's cash runway into 2029 and facilitate the advancement of EQ504, which targets ulcerative colitis. This financing is seen as a strong endorsement of Equillium's strategy.
Read more →EQEquillium to Participate in the Leerink Partners 2026 Global Healthcare Conference
Equillium, Inc. announced its participation in the Leerink Partners 2026 Global Healthcare Conference, scheduled for March 11, 2026. The management team will conduct a fireside chat and is available for investor meetings. The company focuses on novel therapies for severe autoimmune and inflammatory disorders, with its lead candidate EQ504 showing promise in treating conditions like ulcerative colitis.
Read more →EQEquillium to Participate in Upcoming Investor Conferences
Equillium, Inc. announced that its management team will participate in several upcoming investor conferences, including the Piper Sandler 37th Annual Healthcare Conference and the Evercore ISI 8th Annual Healthcare Conference. The format will include fireside chats and one-on-one meetings, allowing for direct interaction with registered investors. This initiative highlights Equillium's ongoing efforts to provide insights into its innovative therapeutics for autoimmune and inflammatory disorders.
Read more →EQ▼ -9.1%on this news
Equillium Reports Third Quarter 2025 Financial Results and Provides Operational Update Closed financing of up to $50 million; initial tranche of $30 million provides runway through 2027 Hosted key opinion leader event hi
Equillium, Inc. released its third quarter financial results for 2025, revealing a significant revenue drop to $0 from $12.2 million in the same quarter last year, primarily due to the termination of previous funding agreements. The company has successfully closed a financing round, generating up to $50 million, which will support the development of EQ504, a novel Aryl Hydrocarbon Receptor modulator aimed at ulcerative colitis. The initial $30 million from the financing is expected to sustain operations through 2027, while a Phase 1 clinical trial for EQ504 is planned to begin in mid-2026.
Read more →EQ▼ -6.5%on this news
Equillium to Host Ulcerative Colitis KOL Event on November 5, 2025
Equillium, Inc. announced a virtual key opinion leader event on November 5, 2025, focusing on ulcerative colitis. Experts will discuss treatment advancements and the potential of EQ504, an oral AhR modulator. The company plans to initiate a Phase 1 study for EQ504 in mid-2026, showcasing its promising preclinical results.
Read more →EQEquillium Announces Leadership and Corporate Updates
Equillium, Inc. announced significant leadership changes and corporate updates aimed at enhancing its focus on the clinical development of EQ504, an investigational aryl hydrocarbon receptor modulator. CEO Bruce Steel emphasized the importance of these changes for improving capital efficiency and advancing therapies for severe inflammatory diseases. Dr. Stephen Connelly has been promoted to President, while the company has also terminated its agreement with Biocon.
Read more →EQ▼ -20.7%on this news
AUGUST 2025 Equillium Announces Strategic Expansion of Cryptocurrency Treasury Reserve Strategy Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammato
Equillium, Inc. has announced a strategic expansion to include cryptocurrency in its treasury reserve strategy as part of its financial goals. This move is intended to enhance diversification and liquidity, while also paving the way for potential long-term capital appreciation. Alongside this new financial strategy, Equillium continues to make progress in developing its investigational therapy, EQ504, for severe autoimmune conditions. The company reports adequate cash reserves expected to fund operations into the fourth quarter of 2025, although it does face risks related to its new cryptocurrency approach and the ongoing need for additional capital.
Read more →EQEquillium Announces Feedback from the U.S. Food and Drug Administration
Equillium, Inc. announced feedback from the FDA following a Type D meeting regarding the regulatory pathway for its drug itolizumab aimed at treating acute graft-versus-host disease. The FDA did not support the Accelerated Approval pathway or the Breakthrough Therapy designation, focusing instead on Day 29 outcomes of the EQUATOR study. However, the FDA expressed a willingness to consider alternative endpoints supported by independent data. Equillium plans to close the EQUATOR study and explore options for advancing itolizumab, amidst financial considerations for future operations.
Read more →EQ▼ -35.6%on this news· ran to -47% by day 1
Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights Announced topline data from the Phase 3 EQUATOR study in first-line acute graft-versus-host disease Break
Equillium, Inc. has reported its 2024 financial results, highlighting topline data from its Phase 3 EQUATOR study for itolizumab in treating acute graft-versus-host disease (aGVHD). While the study did not meet the primary endpoint at Day 29, it showed significant long-term benefits. The company is optimistic following FDA interactions, as it has submitted a request for Breakthrough Therapy designation and accelerated approval. Financially, Equillium noted a decrease in revenue but also a reduction in operating expenses compared to the previous year.
Read more →EQ▼ -8.2%on this news· ran to -20% by day 3
Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates Equillium retains rights to itolizumab following substantial funding from Ono partnership Evaluating accelerating Phase 3
Equillium, Inc. reported its third-quarter 2024 financial results, highlighting the successful retention of rights to itolizumab following a strategic partnership with Ono Pharmaceutical. The company is evaluating the acceleration of its Phase 3 EQUATOR study in acute graft-versus-host disease (aGVHD) to reach topline data by Q1 2025. Financial results showed increased revenue primarily from itolizumab funding and a reduced net loss compared to the previous year. Anticipated data events are set to be pivotal for Equillium as it progresses its clinical pipeline in treating severe autoimmune disorders.
Read more →EQ▼ -37.6%on this news
Itolizumab Update
Equillium, Inc. provided an update on the progress of its drug itolizumab, noting positive interim data from the Phase 3 EQUATOR study for acute graft-versus-host disease (aGVHD). In addition, the company highlighted significant results from the Phase 1b EQUALISE study on lupus nephritis. With topline data for two major studies expected in early 2025, Equillium's existing funding is projected to support operations through Q4 2025. However, the expiration of Ono's option for itolizumab poses a noteworthy strategic setback.
Read more →EQEquillium Reports Second Quarter 2024 Financial Results and Provides Recent Corporate and Clinical Highlights $33.3 million cash balance at the end of Q2 2024, representing a $1.0 million increase from the end of Q1 2024
Equillium Inc. reported its financial results for the second quarter of 2024, highlighting a cash balance of $33.3 million, which is up by $1 million from the previous quarter. The company announced positive interim analyses for its Phase 3 EQUATOR study of itolizumab, along with successful topline data from Phase 1b and Phase 2 studies involving lupus nephritis and alopecia areata, respectively. The firm anticipates a crucial decision from Ono Pharmaceutical regarding the acquisition rights to itolizumab by the end of October 2024, which could provide significant future funding.
Read more →EQ▼ -27.9%on this news· ran to -46% by day 3
This presentation contains forward-looking statements about Equillium, Inc. (the "Company"). In some cases, you can identify forward-looking statements by the words "will," "expect," "intend," "plan," "objective," "belie
Equillium, Inc. presents forward-looking statements regarding EQ101, a first-in-class tri-specific cytokine inhibitor aimed at treating alopecia areata and other conditions. The company highlights the favorable safety profile in previous studies, as well as the unmet need for safer alternatives to existing JAK inhibitors. However, the presentation also outlines significant risks associated with forward-looking statements, and the strong reliance on future regulatory approvals and market acceptance. As the company prepares for further studies, it emphasizes the importance of safety in dermatological treatments.
Read more →EQ▲ +5.9%on this news
Equillium Reports First Quarter 2024 Financial Results and Provides Recent Clinical Highlights $32.3 million cash balance at the end of Q1 2024 expected to provide cash runway into 2H 2025 Announced positive topline data
Equillium Inc. released its financial results for the first quarter of 2024, reporting a cash balance of $32.3 million, which is expected to sustain operations into the second half of 2025. The company highlighted positive topline data from its Phase 1b EQUALISE study of itolizumab in lupus nephritis, with critical upcoming milestones anticipated throughout 2024. Despite a net loss of $2.7 million for the quarter, improvements were noted compared to the previous year, stemming mainly from increased development funding.
Read more →EQ▼ -13.5%on this news· ran to -27% by day 1
Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights $40.9 million cash balance at the end of 2023 expected to provide cash runway into 2H 2025 Completed enrollme
Equillium recently reported its financial results for Q4 and the full year of 2023, highlighting a cash balance of $40.9 million expected to last into the second half of 2025. The company completed enrollment for the Phase 2 clinical study of EQ101 targeting alopecia areata, with topline data anticipated in Q2 2024. Additionally, positive data from the Phase 1b EQUALISE study of itolizumab in lupus nephritis were presented at professional meetings, bolstering the company's clinical progress.
Read more →EQE QUILLIUM , I NC . 2024 I NDUCEMENT P LAN A DOPTED BY THE B OARD OF D IRECTORS
E QUILLIUM, INC. has adopted a 2024 Inducement Plan through its Board of Directors to facilitate the recruitment of new employees and retain existing key personnel. This plan includes the grant of various awards such as stock options and performance cash awards to incentivize maximum efforts for the company's success. Eligible recipients must meet specific criteria and grants will be approved by Independent Directors to comply with Nasdaq regulations.
Read more →EQrisk that studies will not be completed as planned; Equillium's plans and product development, including the initiation and completion of clinical studies and the reporting of data therefrom; changes in the competitive l
Equillium, Inc. has announced promising data from its Phase 1b EQUALISE study of itolizumab for treating lupus nephritis presented at the ASN annual meeting. Key findings indicate that 73% of participants experienced a significant reduction in proteinuria, and the treatment was well-tolerated with a manageable safety profile. Despite the encouraging results, there are concerns about the potential for studies to not complete as planned and the importance of ongoing data reporting. The company plans to share comprehensive data with its strategic partner, Ono Pharmaceutical, early next year.
Read more →EQ▲ +6.7%on this news
Analyst & Investor Day With Dr. Arash Mostaghimi
Equillium, Inc. recently held an Analyst & Investor Day featuring Dr. Arash Mostaghimi among other key speakers. The presentation outlined the company's pipeline, including a first-in-class tri-specific inhibitor, EQ101, targeting alopecia areata and anticipated milestones for clinical trials. Additionally, the company highlighted its partnership with Ono Pharmaceutical for itolizumab, focusing on autoimmune conditions. Overall, the event provided insights into Equillium's strategic goals and product development timelines.
Read more →EQEquillium Reports Second Quarter 2023 Financial Results and Provides Corporate and Clinical Updates $48.4 million in cash at the end of Q2 2023 expected to provide operating runway into 2025 Fully prepaid and retired deb
Equillium, Inc. reported its second quarter 2023 financial results, showcasing a cash position of $48.4 million expected to sustain operations until 2025. The company retired its debt and initiated a $7.5 million stock repurchase program. While the net loss decreased from the previous year, the cash burn rate for research and development remains a concern. The company anticipates milestone data from clinical studies in the upcoming months, which could further support its valuation.
Read more →EQEquillium Reports First Quarter 2023 Financial Results and Provides Clinical Updates $62.0 million cash balance at the end of Q1 2023 expected to provide operating runway into 2025 Presented Phase 1b EQUATE data in aGVHD
Equillium, a clinical-stage biotechnology company, reported robust first quarter 2023 financial results, including a cash balance of $62.0 million expected to extend its operational runway into 2025. The company presented favorable Phase 1b EQUATE trial data for acute graft-versus-host disease, indicating high rates of clinical response and steroid tapering. Ongoing clinical programs for its multi-cytokine inhibitors EQ101 and EQ102 are progressing, with significant upcoming milestones anticipated for the year. However, Equillium still experienced a net loss of $3.9 million in Q1 2023, highlighting ongoing financial challenges.
Read more →EQEquillium Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate & Clinical Development Updates $71.0 million cash balance at the end of 2022 expected to provide cash runway into 2025 Acquired
Equillium, Inc. reported its financial results for the fourth quarter and full year 2022, highlighting a strong cash balance of $71 million that is projected to sustain operations into 2025. The company acquired Bioniz Therapeutics, introducing two new clinical-stage assets, EQ101 and EQ102. Both of these assets have entered clinical studies, with data expected to be announced later in the year. Equillium also secured a strategic partnership with Ono Pharmaceutical, leading to substantial upfront and potential milestone payments.
Read more →EQEquillium and Metacrine Mutually Agree to Terminate Definitive Merger Agreement
Equillium and Metacrine Mutually Agree to Terminate Definitive Merger Agreement LA JOLLA, California, December 23, 2022 Equillium, Inc. (Nasdaq: EQ) and Metacrine, Inc. today announced the mutual termination of their previously announced definitive merger agreement. Equillium
Read more →EQEquillium and Ono Pharmaceutical Announce Exclusive Option and Asset Purchase Agreement for the Development and Commercialization of Itolizumab Equillium grants Ono an option to purchase rights to itolizumab Equillium to
Equillium and Ono Pharmaceutical Announce Exclusive Option and Asset Purchase Agreement for the Development and Commercialization of Itolizumab Equillium grants Ono an option to purchase rights to itolizumab Equillium to receive an upfront payment of approximately $26.0M ( 3.5
Read more →EQEquillium Reports Third Quarter 2022 Financial Results and Provides Corporate and Clinical Updates Announced positive interim results from the EQUALISE study of itolizumab in highly proteinuric lupus nephritis patients:
Equillium Reports Third Quarter 2022 Financial Results and Provides Corporate and Clinical Updates Announced positive interim results from the EQUALISE study of itolizumab in highly proteinuric lupus nephritis patients: by week 28, 83% achieved complete or partial response, and
Read more →EQ▲ +22.8%on this news
Safe Harbor Statement This presentation contains forward-looking statements about Equillium, Inc. (the "Company"). Statements contained in this presentation regarding matters that are not historical facts are "forward-lo
EQUALISE Interim Data Type B: Lupus Nephritis Patients 27 September 2022 Exhibit 99.1 Safe Harbor Statement This presentation contains forward-looking statements about Equillium, Inc. (the "Company"). Statements contained in this presentation regarding matters that are not his
Read more →EQReport of Independent Registered Public Accounting Firm To the Stockholders and the Board of Directors of Metacrine, Inc. Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets o
Report of Independent Registered Public Accounting Firm To the Stockholders and the Board of Directors of Metacrine, Inc. Opinion on the Financial Statements accompanying consolidated balance sheets of Metacrine, Inc. (the Company) as of December 31, 2021 and 2020, the related
Read more →EQEquillium to Acquire Metacrine in All-Stock Transaction Expected to add $33 million in cash at closing to Equillium s balance sheet and extend operating runway into 2024 Acquisition includes novel drug candidate MET642,
Equillium to Acquire Metacrine in All-Stock Transaction Expected to add $33 million in cash at closing to Equillium s balance sheet and extend operating runway includes novel drug candidate MET642, an orally delivered Phase 2 ready FXR agonist for Preston Klassen, M.D., MHS, t
Read more →EQEquillium Reports Second Quarter 2022 Financial Results and Provides Clinical Development Updates
Equillium Reports Second Quarter 2022 Financial Results and Provides Clinical Development Updates LA JOLLA, California, August 15, 2022 Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and i
Read more →EQEquillium Reports First Quarter 2022 Financial Results and Provides Corporate and Clinical Development Updates Initiated EQUATOR Phase 3 study of itolizumab in first-line aGVHD Acquired Bioniz Therapeutics, adding two fi
Equillium Reports First Quarter 2022 Financial Results and Provides Corporate and Clinical Development Updates Initiated EQUATOR Phase 3 study of itolizumab in first-line aGVHD Acquired Bioniz Therapeutics, adding two first-in-class clinical-stage assets to pipeline and propr
Read more →EQEquillium Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate & Clinical Development Updates Announced positive topline data from EQUATE study of itolizumab in first-line aGVHD Initiated EQ
Equillium Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate & Clinical Development Updates Announced positive topline data from EQUATE study of itolizumab in first-line aGVHD Initiated EQUATOR Phase 3 study of itolizumab in first-line aGVHD Pr
Read more →EQEquillium Announces Initiation of the Phase 3 EQUATOR Study of Itolizumab in First-line Acute Graft-Versus-Host Disease Pivotal study to enroll up to 200 patients Global study with sites expected in North America, Europe
Equillium Announces Initiation of the Phase 3 EQUATOR Study of Itolizumab in First-line Acute Graft-Versus-Host Disease Pivotal study to enroll up to 200 patients Global study with sites expected in North America, Europe, Asia and Australia Primary endpoint assessment of Comp
Read more →EQEquillium Announces Appointment of Barbara Troupin to Board of Directors
Equillium Announces Appointment of Barbara Troupin to Board of Directors LA JOLLA, California, March 1, 2022 - Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with
Read more →EQEquillium Acquires Bioniz Therapeutics Significantly Expanding Pipeline of Novel Immunomodulatory Drug Candidates Acquisition includes two first-in-class clinical-stage assets and proprietary product discovery platform C
Equillium Acquires Bioniz Therapeutics Significantly Expanding Pipeline of Novel Immunomodulatory Drug Candidates Acquisition includes two first-in-class clinical-stage assets and proprietary product discovery platform Creates a robust immunology pipeline with significant val
Read more →EQ▼ -5.2%on this news
Equillium Reports Third Quarter 2021 Financial Results and Provides Clinical Development Updates Announced plans to initiate a pivotal study of itolizumab in first-line treatment of acute graft-versus-host disease Report
Equillium Reports Third Quarter 2021 Financial Results and Provides Clinical Development Updates Announced plans to initiate a pivotal study of itolizumab in first-line treatment of acute graft-versus-host disease Reported decrease in proteinuria observed in subgroup of patie
Read more →EQEquillium Reports Second Quarter 2021 Financial Results and Provides Clinical Development Update Announced positive topline results from the EQUATE study of itolizumab in first-line treatment of acute graft-versus-host d
Equillium Reports Second Quarter 2021 Financial Results and Provides Clinical Development Update Announced positive topline results from the EQUATE study of itolizumab in first-line treatment of acute graft-versus-host disease Announced plans to initiate a Phase 3 pivotal stu
Read more →EQEquillium Announces Plans to Initiate Phase 3 Pivotal Study of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease Following End-of-Phase 1 Meeting with the FDA Single pivotal Phase 3 study in acute gra
Equillium Announces Plans to Initiate Phase 3 Pivotal Study of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease Following End-of-Phase 1 Meeting with the FDA Single pivotal Phase 3 study in acute graft-versus-host disease to support filing of biologics li
Read more →EQEquillium Announces Positive Topline Results from the EQUATE Study in First-line Treatment of Acute Graft-Versus-Host Disease Itolizumab continues to demonstrate favorable safety and efficacy profile Rapid and durable re
Equillium Announces Positive Topline Results from the EQUATE Study in First-line Treatment of Acute Graft-Versus-Host Disease Itolizumab continues to demonstrate favorable safety and efficacy profile Rapid and durable responses resulted in clinically meaningful reduction in co
Read more →EQForward Looking Statements Statements contained in this press release regarding matters that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1
Equillium Presents Data on Target Engagement and Modulation of CD6 on T Cells with Itolizumab at the International Society for Advancement of Cytometry Whole blood and proteomic stabilized blood assay used to elicit clinical pharmacodynamic CD6 biomarker in autoimmune diseases
Read more →EQEquillium Presents Data on Target Engagement and Modulation of CD6 on T Cells with Itolizumab at the International Society for Advancement of Cytometry
LA JOLLA, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced a poster presented yesterday at the CYTO Virtual Interactive Meetin
Read more →EQEquillium to Present at the JMP Securities Life Sciences Conference
LA JOLLA, Calif., June 09, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, announced today that it will present at the JMP Securities Life Sciences Conferenc
Read more →EQEquillium to Collaborate with Oxford University and Kennedy Institute of Rheumatology to Investigate Role of the CD6-ALCAM Pathway and Itolizumab in Rheumatic Diseases
Equillium to Collaborate with Oxford University and Kennedy Institute of Rheumatology to Investigate Role of the CD6-ALCAM Pathway and Itolizumab in Rheumatic Diseases LA JOLLA, California, June 7, 2021 Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developi
Read more →EQEquillium to Host Conference Call Following Presentation of Data from the EQUATE Study in Acute Graft Versus Host Disease at the EHA2021 Virtual Congress of the European Hematology Association on June 11
Presentation and conference call will include topline data from all cohorts The risk-benefit profile observed supports advancing development of itolizumab in first-line therapy LA JOLLA, Calif.., June 03, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage b
Read more →EQEquillium to Present at the Jefferies Virtual Healthcare Conference
LA JOLLA, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, announced today that it will present at the Jefferies Virtual Healthcare Conference
Read more →EQEquillium Presents Multiple Posters at the 104th Annual Meeting of the American Association of Immunologists
Research highlights itolizumab’s novel mechanism of action and its effect on modulating T cell responses through inhibition of the CD6-ALCAM pathway The development of a pharmacodynamic biomarker assay to monitor target engagement and fate of CD6 on T cells in patients treated w
Read more →EQEquillium Announces Oral Presentation Highlighting Positive Data from the EQUATE Study in Acute Graft-Versus-Host Disease at the EHA2021 Virtual Congress of the European Hematology Association
LA JOLLA, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that an abstract highlighting positive data from the EQUATE study o
Read more →EQEquillium Reports First Quarter 2021 Financial Results and Provides Clinical Development Update Announced favorable data from Phase 1b EQUALISE study in patients with systemic lupus erythematosus Cash runway into the sec
Equillium Reports First Quarter 2021 Financial Results and Provides Clinical Development Update Announced favorable data from Phase 1b EQUALISE study in patients with systemic lupus erythematosus Cash runway into the second half of 2023 Multiple data and regulatory catalysts
Read more →EQEquillium Announces Three Abstracts Accepted for Presentation at the 104th Annual Meeting of the American Association of Immunologists
LA JOLLA, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that three posters will be presented at VIRTUAL IMMUNOLOGYTM, the
Read more →EQEquillium Announces Favorable Data From Phase 1b EQUALISE Study in Systemic Lupus Erythematosus Patients Itolizumab administered subcutaneously was safe and well tolerated in patients with systemic lupus erythematosus Do
Equillium Announces Favorable Data From Phase 1b EQUALISE Study in Systemic Lupus Erythematosus Patients Itolizumab administered subcutaneously was safe and well tolerated in patients with systemic lupus erythematosus Dose-dependent changes in pharmacodynamic markers observed
Read more →EQEquillium Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Clinical Development Update Cash runway into the second half of 2023 Announced positive interim data from EQUATE study in aGVHD Multiple
Equillium Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Clinical Development Update Cash runway into the second half of 2023 Announced positive interim data from EQUATE study in aGVHD Multiple data and regulatory catalysts in 2021 LA JOLLA, Califor
Read more →EQEquillium Announces Positive Data for Itolizumab in Acute Graft-Versus-Host Disease in Two Presentations at the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation EQUATE acute graft-versus h
Equillium Announces Positive Data for Itolizumab in Acute Graft-Versus-Host Disease in Two Presentations at the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation EQUATE acute graft-versus host disease (aGVHD) study observed rapid response and dura
Read more →EQSafe Harbor Statement This presentation contains forward-looking statements about Equillium, Inc. (the "Company"). In some cases, you can identify forward-looking statements by the words "will," "expect," "intend," "plan
Harnessing Novel Immunobiology www.equilliumbio.com Safe Harbor Statement This presentation contains forward-looking statements about Equillium, Inc. (the "Company"). In some cases, you can identify forward-looking statements by the words "will," "expect," "intend," "plan," "ob
Read more →EQEquillium to Present at the H.C. Wainwright Global Life Sciences Conference
LA JOLLA, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, announced today that it will present at the H.C. Wainwright Global Life Sciences
Read more →EQEquillium to Present at the SVB Leerink 10th Annual Global Healthcare Conference
LA JOLLA, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, announced today that it will present at the SVB Leerink 10th Annual Global Healthc
Read more →EQEquillium Presents Positive Interim Clinical Data of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease at the 2021 Transplantation and Cellular Therapy Meetings Digital Experience
Higher dose cohorts demonstrated 100% overall response rate, resulting in substantial reduction in baseline corticosteroid use Dose-dependent reduction of CD6 expression on CD4+ and CD8+ T cells is consistent with itolizumab mechanism of action LA JOLLA, Calif., Feb. 12, 2021 (
Read more →EQJohn Koreth, Alison W. Loren, Ryotaro Nakamura, Marco Mielcarek, Trent Wang, George L. Chen, Sarah Anand, Joseph A. Pidala, Edmund K. Waller, Gabrielle Meyers, Daanish Hoda, Mark Schroeder, Jeremy Pantin, Nosha Farhadfar
Research Support: BMS, Miltenyi, Clinigen, Amgen, Regeneron Advisory Board: Therakos, Cugene, Regeneron Consulting: EMD Serono/Merck, Biolojic Design, Gentibio, Moderna Therapeutics, Equillium, Inc Investigational use of Itolizumab (EQ001) for aGVHD Disclosures 2 CD6 is a co-
Read more →EQEquillium Announces the Appointment of Katherine Xu to the Board of Directors
LA JOLLA, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that Y. Katherine Xu, Ph.D., partner at Decheng Capital, has been a
Read more →EQEquillium Announces Closing of $30 Million Registered Direct Offering
LA JOLLA, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced the closing of its previously announced registered direct offering
Read more →EQEquillium Announces Pricing of $30 Million Registered Direct Offering
Equillium Announces Pricing of $30 Million Registered Direct Offering LA JOLLA, Calif., February 4, 2021 - Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that it has
Read more →EQEquillium Announces Acceptance of Late-Breaking Abstract for Oral Presentation of Interim Data from EQUATE Study in acute GVHD at the 2021 TCT Meetings Digital Experience
LA JOLLA, Calif., Jan. 22, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that interim data from the Phase 1b/2 EQUATE study of itolizumab in
Read more →EQEquillium to Present at the H.C. Wainwright Virtual BioConnect Conference
LA JOLLA, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that Bruce Steel, Equillium’s chief executive officer, will present
Read more →EQEquillium Appoints Industry Veteran, Dolca Thomas, M.D. as Executive Vice President of Research & Development and Chief Medical Officer Equillium Further Strengthens Management Team with Additional Executive Hires
Equillium Appoints Industry Veteran, Dolca Thomas, M.D. as Executive Vice President of Research & Development and Chief Medical Officer Equillium Further Strengthens Management Team with Additional Executive Hires LA JOLLA, Calif., Dec. 21, 2020 Equillium, Inc. (Nasdaq: EQ) a
Read more →EQEquillium Presents Translational Data Demonstrating Impact of Itolizumab on Effector T Cell Function at the 2020 American Society of Hematology Annual Meeting and Exposition Studies further support itolizumab s potential
Equillium Presents Translational Data Demonstrating Impact of Itolizumab on Effector T Cell Function at the 2020 American Society of Hematology Annual Meeting and Exposition Studies further support itolizumab s potential as treatment for aGVHD patients LA JOLLA, Calif., Dec. 7
Read more →EQEquillium to Host Virtual Investor and Analyst Day on
Equillium to Host Virtual Investor and Analyst Day on December 4, 2020 Review positive interim data from the study of itolizumab for the treatment of acute GVHD and pipeline programs in lupus / lupus nephritis and uncontrolled asthma Featured guest speaker: John Koreth, M.D.,
Read more →EQEquillium Provides Itolizumab COVID-19 Program Update Analyst Day scheduled for
Equillium Provides Itolizumab COVID-19 Program Update Analyst Day scheduled for December 4, 2020 LA JOLLA, Calif., Nov 25, 2020 -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,
Read more →EQEquillium to Present at Investor Conferences in November 2020
LA JOLLA, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that Bruce Steel, Equillium’s chief executive officer and Krishna
Read more →EQEquillium Reports Third Quarter 2020 Financial Results and Business Highlights
Equillium Reports Third Quarter 2020 Financial Results and Business Highlights LA JOLLA, Calif., Nov 10, 2020 Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced financ
Read more →EQEquillium Announces Positive Interim Data of Itolizumab in the First-line Treatment of Acute Graft-Versus-Host Disease
100% overall response rate in dose cohort 3 and 80% overall response rate across all cohorts to date Complete response observed in seven of eight responding patients EQUATE Phase 1b topline data expected during first half 2021 LA JOLLA, Calif., Nov. 06, 2020 (GLOBE NEWSWIRE) -
Read more →EQEquillium to Present Data at the 2020 American College of Rheumatology Meeting Demonstrating CD6 Modulation Improves Kidney and Skin Pathology in Preclinical Models of Systemic Lupus Erythematosus
Studies further validate ongoing clinical development of itolizumab for the treatment of systemic lupus erythematosus and lupus nephritis LA JOLLA, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical stage biotechnology company developing novel immu
Read more →EQEquillium Receives FDA Clearance of COVID-19 IND for Phase 3 Trial Equillium plans to initiate global Phase 3 COVID-19 trial EQUINOX during Q4 2020 FDA indicates study could support BLA filing
Equillium Receives FDA Clearance of COVID-19 IND for Phase 3 Equillium plans to initiate global Phase 3 COVID-19 trial EQUINOX FDA indicates study could support BLA filing LA JOLLA, Calif., Oct. 29, 2020 Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company deve
Read more →EQEquillium Presented New Data and Insights on the CD6-ALCAM Pathway in Uncontrolled Asthma at the European Respiratory Society International Congress 2020
LA JOLLA, Calif., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that data supporting the CD6-ALCAM pathway as a relevant target f
Read more →EQEquillium Announces Successful Completion of FDA Pre-IND Meeting Enabling Advancement of Itolizumab into a Potential Registration Study as a Treatment for Hospitalized COVID-19 Patients
Equillium anticipates filing a U.S. IND for Itolizumab for COVID-19 and initiating a global Phase 3 clinical study in Q4 2020 LA JOLLA, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat
Read more →EQEquillium to Present at H.C. Wainwright 22nd Annual Global Investment Conference
LA JOLLA, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders, today announced that Bruce Ste
Read more →EQEquillium Announces Closing of Public Offering of Common Stock
LA JOLLA, Calif., Aug. 18, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced the closing of its previously announced underwritten public offeri
Read more →EQEquillium Announces Pricing of Public Offering of Common Stock
LA JOLLA, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced the pricing of an underwritten public offering of 5,000,000 shares
Read more →EQEquillium Announces Proposed Public Offering of Common Stock
Equillium Announces Proposed Public Offering of Common Stock LA JOLLA, Calif., August 13, 2020 Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that it intends to of
Read more →EQEquillium Reports Second Quarter 2020 Financial Results and Recent Highlights
Equillium Reports Second Quarter 2020 Financial Results and Recent Highlights LA JOLLA, Calif., August 12, 2020 Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced fina
Read more →EQEquillium Announces Positive Interim Data with Itolizumab in Acute GVHD Study Complete response observed in five of seven patients in first two dose cohorts COVID-19 Pre-IND meeting request and briefing package submitted
Equillium Announces Positive Interim Data with Itolizumab in Acute GVHD Study Complete response observed in five of seven patients in first two dose cohorts COVID-19 Pre-IND meeting request and briefing package submitted to the FDA LA JOLLA, Calif., August 10, 2020 Equillium,
Read more →EQEquillium to Present at BTIG Virtual Biotechnology Conference 2020
LA JOLLA, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders, today announced that Bruce Stee
Read more →EQClinical Trial Shows Itolizumab Reduces Mortality in Patients Hospitalized with COVID-19 Equillium shares topline results of patients treated with itolizumab in clinical trial conducted in India by partner Biocon Biocon
Clinical Trial Shows Itolizumab Reduces Mortality in Patients Hospitalized with COVID-19 Equillium shares topline results of patients treated with itolizumab in clinical trial conducted in India by partner Biocon Biocon has received emergency use approval from Drugs Controller
Read more →EQEquillium to Present at Jefferies Virtual Healthcare Conference
LA JOLLA, Calif., May 21, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders, today announced that Bruce Steel
Read more →EQEquillium Reports First Quarter 2020 Financial Results
Equillium Reports First Quarter 2020 Financial Results LA JOLLA, Calif., May 13, 2020 -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders,
Read more →EQEquillium to Present at 2020 RBC Capital Markets Virtual Global Healthcare Conference
LA JOLLA, Calif., May 07, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders, today announced that Bruce Steel
Read more →EQEquillium Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital
LA JOLLA, Calif., March 30, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders, today announced it has entered into
Read more →EQEquillium Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Business Update EQUIP and EQUALISE Studies to be Paused in Response to the COVID-19 Pandemic Company Reaffirms Guidance to Report Initial
Equillium Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Business Update EQUIP and EQUALISE Studies to be Paused in Response to the Company Reaffirms Guidance to Report Initial Data from the EQUATE Trial in Acute GVHD in 2H 2020 LA JOLLA, Calif., Mar
Read more →EQEquillium Strengthens Leadership Team with Key Appointments
Maple Fung, M.D., joins as vice president clinical development Matthew Ritter, Ph.D., joins as vice president corporate development LA JOLLA, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understan
Read more →EQEquillium to Present at 9th Annual SVB Leerink Global Healthcare Conference
LA JOLLA, Calif., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders, today announced that Bruce Stee
Read more →EQEquillium to Present Translational Preclinical Data Demonstrating Increased Survival and Decreased Disease Severity in Models of Graft-Versus-Host Disease Treated with Itolizumab at the Transplantation & Cellular Therapy Meetings of ASTCT & CIBMTR
LA JOLLA, Calif., Jan. 29, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders, today announced that translational da
Read more →EQEquillium & Biocon Expand Exclusive Licensing Agreement for Itolizumab to Include Australia and New Zealand LA JOLLA, Calif. / BENGALURU, Karnataka, India
Equillium & Biocon Expand Exclusive Licensing Agreement for Itolizumab to Include Australia and New Zealand LA JOLLA, Calif. / BENGALURU, Karnataka, India, December 12, 2019 Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of im
Read more →EQEquillium Granted U.S. FDA Fast Track Designation for Itolizumab for the Treatment of Lupus Nephritis
LA JOLLA, Calif., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders, today announced that the U.S. Food an
Read more →EQEquillium to Present Translational Data on Itolizumab for Acute Graft-Versus-Host Disease at 61st American Society of Hematology (ASH) Annual Meeting and Exposition
LA JOLLA, Calif., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders, today announced that data supporting
Read more →EQEquillium Featured in Panel Discussion at Capital Markets Day for Kidney Health
LA JOLLA, Calif., Nov. 15, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders, today announced that Krishna R. Polu,
Read more →EQEquillium Announces Leadership Updates
Effective January 1, 2020 Bruce Steel will assume role of Chief Executive Officer, and Dan Bradbury will remain on the Board of Directors as Executive Chairman Krishna Polu, M.D., and Christine Zedelmayer will be promoted to Executive Vice President Research & Development and
Read more →EQEquillium Reports Third Quarter 2019 Financial Results and Recent Highlights
Equillium Reports Third Quarter 2019 Financial Results and Recent Highlights LA JOLLA, November 12, 2019 - Equillium, Inc. (Nasdaq: EQ), a biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorde
Read more →EQEquillium to Present at Investor Conferences in November 2019
LA JOLLA, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders, today announced that Bruce Steel, Equ
Read more →EQEquillium to Present New Data and Insights on the CD6-ALCAM Pathway in Lupus Nephritis at ACR 2019
LA JOLLA, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders, today announced that data describing
Read more →EQCompany Logo harnessing novel immunobiology October 2019 www. Equilliumbio.com Safe Harbor Statement This presentation contains forward-looking statements about Equillium, Inc. (the "Company"). In some cases, you can ide
Company Logo harnessing novel immunobiology October 2019 www. Equilliumbio.com Safe Harbor Statement This presentation contains forward-looking statements about Equillium, Inc. (the "Company"). In some cases, you can identify forward-looking statements by the words "will," "expe
Read more →EQEquillium Announces Initiation of the EQUALISE Phase 1b Clinical Trial of Itolizumab for Patients with Lupus Nephritis and Provides Business Update
Company secures up to $20 million debt facility with Silicon Valley Bank and Oxford Finance LLC Company receives exclusive rights to negotiate licensing rights to develop and commercialize itolizumab in select major markets outside of North America Management to host conference
Read more →EQEquillium to Host Business Update Call on October 1, 2019
LA JOLLA, Calif., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company, leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders will be hosting a call with sharehol
Read more →EQEquillium to Present at H. C. Wainwright 21st Annual Global Investment Conference
LA JOLLA, Calif., Aug. 27, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders, today announced that Bruce Steel, Equ
Read more →EQEquillium Reports Second Quarter 2019 Financial Results and Recent Highlights Initiated Phase 1b EQUIP proof-of-concept trial evaluating itolizumab (EQ001) for the treatment of uncontrolled asthma Investigational New Dru
Equillium Reports Second Quarter 2019 Financial Results and Recent Highlights Initiated Phase 1b EQUIP proof-of-concept trial evaluating itolizumab (EQ001) for the treatment of uncontrolled asthma Investigational New Drug (IND) application accepted by FDA for itolizumab for the
Read more →EQEquillium Announces Initiation of the EQUIP Phase 1b Clinical Trial of Itolizumab for Patients with Uncontrolled Asthma
LA JOLLA, Calif., July 10, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced it has
Read more →EQEquillium to Present at Jefferies 2019 Healthcare Conference
LA JOLLA, Calif., May 23, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders, today announced that Dan Bradbury, Equ
Read more →EQEquillium Reports First Quarter 2019 Financial Results and Recent Highlights EQUATE Phase 1b/2 trial in acute graft-versus-host disease (aGVHD) ongoing with data expected in 1Q 2020 On track to initiate Phase 1b proof-of
Equillium Reports First Quarter 2019 Financial Results and Recent Highlights EQUATE Phase 1b/2 trial in acute graft-versus-host disease (aGVHD) ongoing with data expected in 1Q 2020 On track to initiate Phase 1b proof-of-concept trials of itolizumab (EQ001) in uncontrolled mode
Read more →EQEquillium Expands Scientific and Clinical Advisory Team
LA JOLLA, Calif., May 06, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders with high unmet medical need, today ann
Read more →EQEquillium to Present at Solebury Trout Class of 2018 Biotech IPO Investor Day
LA JOLLA, Calif., April 16, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company developing treatments for severe immuno-inflammatory disorders, today announced that Bruce Steel, Equillium’s president and chief business officer, will present at the Soleb
Read more →EQEquillium to Present at H.C. Wainwright Global Life Sciences Conference
LA JOLLA, Calif., March 28, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company developing treatments for severe immuno-inflammatory disorders, today announced that Dan Bradbury, Equillium’s chairman and chief executive officer, will present at the H.C.
Read more →EQEquillium Reports Fourth Quarter and Full-Year 2018 Financial Results and Recent Highlights Initiated the EQUATE Phase 1b/2 trial in acute graft-versus-host disease in March 2019
Equillium Reports Fourth Quarter and Full-Year 2018 Financial Results and Recent Highlights Initiated the EQUATE Phase 1b/2 trial in acute graft-versus-host disease in March 2019 LA JOLLA, Calif., Mar. 27, 2019 - Equillium, Inc. (Nasdaq: EQ), a biotechnology company leveraging
Read more →EQEquillium Announces Plan to Develop EQ001 for the Treatment of Lupus Nephritis
Clinical trial evaluating EQ001 for the treatment of refractory lupus nephritis to commence in 2H 2019 Ongoing EQ001 development programs in acute graft-versus-host disease and severe asthma remain on-track Company to host conference call today, Tuesday, February 26, at 4:30 p.
Read more →EQEquillium to Present at Leerink Partners Global Healthcare Conference
LA JOLLA, Calif., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company developing treatments for severe immune-inflammatory disorders, announced today that Bruce Steel, Equillium’s president and chief business officer, will present at the Leerin
Read more →EQEquillium to Host Business Update Call on February 26
LA JOLLA, Calif., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company developing treatments for severe immune-inflammatory disorders, will be hosting a call with shareholders and the investment community to provide a business update on Tuesday,
Read more →EQEquillium Granted U.S. FDA Orphan Drug Designations for EQ001 (itolizumab) for both the Prevention and Treatment of Acute Graft-Versus-Host Disease
LA JOLLA, Calif., Feb. 07, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company developing treatments for severe immuno-inflammatory disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designations for EQ00
Read more →EQEquillium Granted U.S. FDA Fast Track Designation for EQ001 for the Treatment of Acute Graft-Versus-Host Disease
LA JOLLA, Calif., Dec. 19, 2018 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company developing treatments for severe immuno-inflammatory disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for EQ001
Read more →EQEquillium Reports Third Quarter 2018 Financial Results and Recent Highlights Completes Successful Initial Public Offering Raising Gross Proceeds of Approximately $71.6 Million On-Track for Early 2019 Initiation Phase 1b/
Equillium Reports Third Quarter 2018 Financial Results and Recent Highlights Completes Successful Initial Public Offering Raising Gross Proceeds of Approximately $71.6 Million On-Track for Early 2019 Initiation Phase 1b/2 Trial of EQ001 in Acute Graft-Versus-Host Disease LA JO
Read more →EQHarnessing Novel Immunobiology November 2018 Safe Harbor Statement This presentation contains forward-looking statements about Equillium, Inc. (the "Company"). In some cases, you can identify forward-looking statements b
Harnessing Novel Immunobiology November 2018 Safe Harbor Statement This presentation contains forward-looking statements about Equillium, Inc. (the "Company"). In some cases, you can identify forward-looking statements by the words "will," "expect," "intend," "plan," "objective
Read more →EQEquillium to Present at Investor Conferences in November 2018
LA JOLLA, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that Br
Read more →EQEquillium Announces Pricing of Initial Public Offering
LA JOLLA, Calif., Oct. 12, 2018 (GLOBE NEWSWIRE) -- Equillium Inc. (Nasdaq: EQ), a biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced the pric
Read more →Competitive Position
How EQ ranks across every disease it competes inCompetitive Position is a premium feature
See how EQ ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial